首站-论文投稿智能助手
典型文献
ACT001 inhibits pituitary tumor growth by inducing autophagic cell death via MEK4/MAPK pathway
文献摘要:
ACT001,derived from traditional herbal medicine,is a novel compound with effective anticancer activity in clinical trials.However,little is known regarding its role in pituitary adenomas.Here,we demonstrated that ACT001 suppressed cell proliferation and induced cell death of pituitary tumor cells in vitro and in vivo.ACT001 was also effective in suppressing the growth of different subtypes of human pituitary adenomas.The cytotoxic mechanism ACT001 employed was mainly related to autophagic cell death(ACD),indicated by autophagosome formation and LC3-Ⅱ accumulation.In addition,ACT001-mediated inhibitory effect decreased when either ATG7 was downregulated or cells were cotreated with autophagy inhibitor 3-methyladenine(3-MA).RNA-seq analysis showed that mitogen-activated protein kinase(MAPK)pathway was a putative target of ACT001.Specifically,ACT001 treatment promoted the phosphorylation of JNK and P38 by binding to mitogen-activated protein kinase kinase 4(MEK4).Our study indicated that ACT001-induced ACD of pituitary tumor cells via activating JNK and P38 phosphorylation by binding with MEK4,and it might be a novel and effective anticancer drug for pituitary adenomas.
文献关键词:
作者姓名:
Lin Cai;Ze-rui Wu;Lei Cao;Jia-dong Xu;Jiang-long Lu;Cheng-de Wang;Jing-hao Jin;Zhe-bao Wu;Zhi-peng Su
作者机构:
Department of Neurosurgery,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou 325000,China;Department of Neurosurgery,Beijing Tiantan Hospital,Capital Medical University,Beijing 100050,China;Department of Cardio-Thoracic Surgery,Zhoushan Hospital,Zhoushan 316021,China;Department of Neurosurgery,Center of Pituitary Tumor,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
引用格式:
[1]Lin Cai;Ze-rui Wu;Lei Cao;Jia-dong Xu;Jiang-long Lu;Cheng-de Wang;Jing-hao Jin;Zhe-bao Wu;Zhi-peng Su-.ACT001 inhibits pituitary tumor growth by inducing autophagic cell death via MEK4/MAPK pathway)[J].中国药理学报(英文版),2022(09):2386-2396
A类:
ACT001,MEK4
B类:
inhibits,pituitary,tumor,growth,by,inducing,autophagic,death,via,MAPK,pathway,derived,from,traditional,herbal,medicine,novel,compound,effective,anticancer,activity,clinical,trials,However,little,known,regarding,role,adenomas,Here,demonstrated,that,suppressed,proliferation,induced,cells,vitro,vivo,was,also,suppressing,different,subtypes,human,cytotoxic,mechanism,employed,mainly,related,ACD,indicated,autophagosome,formation,LC3,accumulation,In,addition,mediated,inhibitory,decreased,when,either,ATG7,downregulated,were,cotreated,autophagy,methyladenine,seq,analysis,showed,mitogen,activated,protein,kinase,putative,target,Specifically,treatment,promoted,phosphorylation,JNK,P38,binding,Our,study,activating,might,be,drug
AB值:
0.504688
相似文献
Globular adiponectin-mediated vascular remodeling by affecting the secretion of adventitial-derived tumor necrosis factor-αinduced by urotensin Ⅱ
Jun LI;Limin LUO;Yonggang ZHANG;Xiao DONG;Shuyi DANG;Xiaogang GUO;Wenhui DING-Department of Cardiology,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China;Division of Cardiology,Department of Internal Medicine,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,China;Division of Cardiology,Department of Internal Medicine,Peking University First Hospital,Beijing 100034,China;Department of Dermatology,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China;Department of Cardiovascular Diseases,the Second Affiliated Hospital,Shantou University Medical College,Shantou 515041,China
FGF2 is overexpressed in asthma and promotes airway inflammation through the FGFR/MAPK/NF-κB pathway in airway epithelial cells
Yuan-Yang Tan;Hui-Qin Zhou;Yu-Jing Lin;Liu-Tong Yi;Zhuang-Gui Chen;Qing-Dong Cao;Yan-Rong Guo;Zhao-Ni Wang;Shou-Deng Chen;Yang Li;De-Yun Wang;Yong-Kang Qiao;Yan Yan-Guangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong Provincial Engineering Research Center,the Fifth Affiliated Hospital,Sun Yat-Sen University,Zhuhai 519000,Guangdong,China;Department of Pathology,the Fifth Affiliated Hospital,Sun Yat-Sen University,Zhuhai 519000,Guangdong,China;Department of Pediatrics,the Third Affiliated Hospital,Sun Yat-Sen University,Guangzhou 510630,China;Department of Cardiothoracic Surgery,the Fifth Affiliated Hospital,Sun Yat-Sen University,Zhuhai 519000,Guangdong,China;Department of Otolaryngology,Yong Loo Lin School of Medicine,National University Health System,National University of Singapore,Singapore 119228,Singapore;BGI-Shenzhen,Shenzhen 518083,Guangdong,China;Central Laboratory,the Fifth Affiliated Hospital,Sun Yat-Sen University,Zhuhai 519000,Guangdong,China
Overexpressed NEDD8 as a potential therapeutic target in esophageal squamous cell carcinoma
Jingrong Xian;Shiwen Wang;Yanyu Jiang;Lihui Li;Lili Cai;Ping Chen;Yue Liu;Xiaofei Zeng;Guoan Chen;Chen Ding;Robert M.Hoffman;Lijun Jia;Hu Zhao;Yanmei Zhang-Department of Laboratory Medicine,Huadong Hospital Affiliated to Fudan University,Shanghai 200040,China;Cancer Institute,Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China;Research Center on Aging and Medicine,Fudan University,Shanghai 200040,China;Shanghai Key Laboratory of Clinical Geriatric Medicine,Shanghai 200040,China;Department of Basic Science of Oncology,College of Basic Medical Sciences,Zhengzhou University,Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;School of Medicine,Southern University of Science and Technology,Shenzhen 518055,China;State Key Laboratory of Genetic Engineering,Human Phenome Institute,Institutes of Biomedical Sciences,School of Life Sciences,Zhongshan Hospital,Fudan University,Shanghai 200032,China;State Key Laboratory of Cell Differentiation and Regulation,Henan International Joint Laboratory of Pulmonary Fibrosis,Henan Center for Outstanding Overseas Scientists of Pulmonary Fibrosis,College of Life Science,Institute of Biomedical Science,Henan Normal University,Xinxiang 453007,China;Department of Surgery,University of California,San Diego 92101,USA;Anticancer Inc.,San Diego 92101,USA
Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
Leyi Yao;Qian Zhao;Ding Yan;Ziying Lei;Yali Hao;Jinghong Chen;Qian Xue;Xiaofen Li;Qingtian Huang;Daolin Tang;Q.Ping Dou;Xin Chen;Jinbao Liu-Affiliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,State Key Laboratory of Respiratory Disease,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;Institute of Digestive Disease of Guangzhou Medical University,The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan 511518,China;School of Public Health,Guangzhou Medical University,Guangzhou,511436,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
Exosomal miR-485-3p derived from pancreatic ductal epithelial cells inhibits pancreatic cancer metastasis through targeting PAK1
Li Mingzhe;Zhou Jiaxin;Zhang Zhengkui;Li Jisong;Wang Feng;Ma Ling;Tian Xiaodong;Mao Zebin;Yang Yinmo-Department of General Surgery, Peking University First Hospital, Beijing 100034, China;Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang 310016, China;Department of Gastrointestinal Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, China;Department of Surgical Oncology, Peking University Ninth School of Clinical Medicine (Beijing Shijitan Hospital, Capital Medical University), Beijing 100038, China;Department of Medical Biochemistry and Molecular Biology, Peking University Health Science Center, Beijing 100191, China
Taxifolin attenuates inflammation via suppressing MAPK signal pathway in vitro and in silico analysis
Xingyan Zhang;Xiaoyan Lian;Huling Li;Wenjing Zhao;Xin Li;Fujun Zhou;Yutong Zhou;Tao Cui;Yuli Wang;Changxiao Liu-Key Laboratory of Quality-marker of Traditional Chinese Medicines,Tianjin Institute of Pharmaceutical Research Co.,Ltd.,Tianjin 300462,China;Center for Drug Evaluation,National Medical Products Administration,Beijing 100022,China;Department of Pharmacology,Tianjin Medical University,Tianjin 300070,China;State Key Laboratory of Drug Delivery Technology and Pharmacokinetics,Tianjin Institute of Pharmaceutical Research Co.,Ltd.,Tianjin 300462,China;Key Laboratory of Systems Bioengineering(Ministry of Education),School of Chemistry Engineering and Technology,Tianjin University,Tianjin 300072,China;Pharmaceuticai Armaceuticai DA REN TANG Group Corporation Limited Traditional Chinese Pharmacy Researchinstitute,Tianjin 300457,China;Tianjin Key Laboratory of Quality Control in Chinese Medicine,Tianjin 300457,China;Research Unit for Drug Metabolism,Chinese Academy of Medical Sciences,Beijing 100730,China
Eupalinolide B inhibits hepatic carcinoma by inducing ferroptosis and ROS-ER-JNK pathway
Yonghui Zhang;Haoyang Zhang;Jinage Mu;Meiyue Han;Zhihao Cao;Feng Dong;Tingting Wang;Lian Pan;Wujing Luo;Jiaxin Li;Huan Liu;Lishan Jin;Wenxuan Ding;Yong Wei;Xuesong Deng;Dan Liu;Xiuzhen He;Yi Pang;Xiao Mu;Zhongjun Wu;Dilong Chen-The First Affiliated Hospital of Chongqing Medical University,Chongqing 400042,China;The People's Hospital Affiliated to Chongqing Three Gorges Medical College,Chongqing 404100,China;Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area,Chongqing 404120,China;Chongqing Engineering Research Center of Antitumor Natural Drugs,Chongqing 404120,China;Key Laboratory of Intelligent Information Processing and Control,College of Electronic and Information Engineering,Chongqing Three Gorges University,Chongqing 404110,China
Structures of the endogenous peptide-and selective non-peptide agonist-bound SSTR2 signaling complexes
Li-Nan Chen;Wei-Wei Wang;Ying-Jun Dong;Dan-Dan Shen;Jia Guo;Xuefei Yu;Jiao Qin;Su-Yu Ji;Huibing Zhang;Qingya Shen;Qiaojun He;Bo Yang;Yan Zhang;Qinglin Li;Chunyou Mao-Department of Biophysics and Department of Pathology of Sir Run Run Shaw Hospital,Zhejiang University,School of Medicine,Hangzhou,Zhejiang,China;Department of General Surgery,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine,Hangzhou,Zhejiang,China;Center for Structural Pharmacology and Therapeutics Development,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine,Hangzhou,Zhejiang,China;Liangzhu Laboratory,Zhejiang University Medical Center,Hangzhou,Zhejiang,China;The Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital),Hangzhou,Zhejiang,China;Zhejiang Province Key Laboratory of Anti-Cancer Drug Research,College of Pharmaceutical Sciences,Zhejiang University,Hangzhou,Zhejiang,China;MOE Frontier Science Center for Brain Research and Brain-Machine Integration,Zhejiang University School of Medicine,Hangzhou,Zhejiang,China;Zhejiang Provincial Key Laboratory of Immunity and Inflammatory diseases,Hangzhou,Zhejiang,China
Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+T cell-mediated ferroptosis in castration-resistant prostate cancer
Xumin Zhou;Libin Zou;Hangyu Liao;Junqi Luo;Taowei Yang;Jun Wu;Wenbin Chen;Kaihui Wu;Shengren Cen;Daojun Lv;Fangpeng Shu;Yu Yang;Chun Li;Bingkun Li;Xiangming Mao-Department of Urology,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Second Department of Hepatobiliary Surgery,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Department of Urology,Minimally Invasive Surgery Center,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;Department of Urology,Guangzhou Women and Children's Medical Center,Guangzhou Medical University,Guangzhou 510623,China;Department of Urology,Peking University Shenzhen Hospital,Shenzhen 518036,China;Nursing Department,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China
Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo
Fanxiang Yin;Ran Zhao;Dhilli Rao Gorja;Xiaorong Fu;Ning Lu;Hai Huang;Beibei Xu;Hanyong Chen;Jung-Hyun Shim;Kangdong Liu;Zhi Li;Kyle Vaughn Laster;Zigang Dong;Mee-Hyun Lee-Department of Pathophysiology,School of Basic Medical Sciences,Zhengzhou University,Zhengzhou 450001,China;China-US(Henan)Hormel Cancer Institute,Zhengzhou 450008,China;Translational Medical Center,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;The Hormel Institute,University of Minnesota,Austin,MN 55912,USA;Department of Biomedicine,Health&Life Convergencen Science,BK21 Four,College of Pharmacy,Mokpo National University,Jeonnam 58554,Republic of Korea;The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;Department of General Surgery,the Affiliated Tumor Hospital of Zhengzhou University,Zhengzhou 450008,China;College of Korean Medicine,Dongshin University,Naju 58245,Republic of Korea
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。